Traumatic brain injuries (TBIs), including concussions, are one of the main public health concerns globally. TBI diagnosis is currently based on clinical assessment using scores such as Glasgow coma scale and computer tomography. However, scores can be compromised for various reasons and the computer tomography is less than perfect too as even in severe cases the findings can be normal.
Glial fibrillary acidic protein (GFAP) can be detected in blood a few hours after head trauma and it has emerged as a very promising biomarker of TBI.
Advanced ImmunoChemical provides several new monoclonal antibodies specific to human GFAP and reagents for S100B, H-FABP and NSE that have been indicated as biomarkers in brain injuries.
We provide several new monoclonal antibodies specific to human GFAP. Prototype immunoassays detect GFAP in clinical samples. The figure below shows GFAP levels in patients suffering from hemorrhagic or ischemic stroke; GFAP has been indicated as a putative marker to allow for differentiation of these two types of strokes. In hemorrhagic stroke GFAP appears in blood much sooner than in the case of acute ischemic stroke.
GFAP was measured in plasma samples from hemorrhagic and ischemic stroke patients by using the GFAP83cc-GFAP81cc prototype assay. All of the samples were taken within the first 12 hours following the injury. The assay only detected GFAP in the plasma samples from patients who suffered a hemorrhagic stroke. This is in line with the results from other studies; in ischemic strokes, the level of GFAP should only increase at a later time point.
S100B, H-FABP and neuron specific enolase (NSE) have been indicated as biomarkers in brain injuries. Please follow the links below to find out more about these.
Browse our website and order online: AdvImmuno.com/Shop
If you are interested in receiving further information or have other questions, please contact us by e-mail at firstname.lastname@example.org.